INTERVENTIONAL ONCOLOGY CORPORATE AND REGIONAL PRESS RELEASES

Please find below a list of our press releases.

19 Jun 2018

Historical Financial Information Restated to US Dollars

Starting with the 2018/19 financial year, BTG will change its presentational currency to the US Dollar. This change is reflective of the fact that the majority of the Group’s revenues and a significant proportion of its operating costs are now denominated in US Dollars. Historical US Dollar income statements, on an IFRS and Adjusted basis, and selected product sales information are presented in the document below.

15 Jun 2018

Result of FDA Advisory Committee vote on Elevair™ for the treatment of severe emphysema

BTG plc (LSE: BTG), the global specialist healthcare company, notes that the US Food & Drug Administration’s (FDA’s) Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee yesterday voted against the approval of the Elevair™ Endobronchial Coil System for the treatment of people with severe emphysema.

11 Jun 2018

ELEVATE study aims to improve selection criteria and outcomes for patients with severe emphysema treated with the PneumRx Endobronchial Coil System

BTG plc (LSE: BTG), the global healthcare company, today announces the start of ELEVATE: A randomizEd ControlLed Study of PnEumRx™ Endobronchial Coil System (Coils) Versus Standard of Care Medical MAnagement in the Treatment of Subjects with Severe Emphysema.

15 May 2018

BTG plc: Final Results 2018

BTG plc (LSE: BTG), the global specialist healthcare company, today announces its final results for the year ended 31 March 2018.

27 Apr 2018

OPTALYSE PE Results Presented at Society for Cardiovascular Angiography and Interventions

BTG plc (LSE: BTG), the global healthcare company, highlighted the presentation of OPTALYSE PE trial results at the Society for Cardiovascular Angiography and Interventions in San Diego, California. The findings further confirm that bilateral pulmonary embolism treated in as little as 2 hours with significantly less tissue plasminogen activator (tPA) than used in previous studies1- as low as 8mg total - show significant improvement in RV/LV ratio over both the short and long term and with a very low mortality rate of 2% and an equally low recurrent PE rate of 2%.

5 Apr 2018

BTG plc: close period update

London, UK, 5 April 2018: BTG plc (LSE: BTG), the global healthcare company, provides the following update for the year ended 31 March 2018. BTG has delivered a good financial performance for the year, with revenue in line with expectations.

21 Feb 2018

First Patient in Latin America Receives TheraSphere® Radioembolisation Treatment

February 28, 2018: BTG plc (LSE: BTG), a global specialist healthcare company, announced the first patient in Latin America in Mexico was treated with TheraSphere® – a treatment for hepatic neoplasia that delivers powerful radiation to tumour cells and minimizes the exposure to healthy tissue.

23 Jan 2018

Appointment of Non-executive Director

BTG plc (LSE: BTG) the specialist healthcare company, today announces the appointment of Anne Thorburn as a non-executive director of the Board and member of the Audit Committee.

14 Dec 2017

Centers Commence Enrollment in KNOCOUT PE Study to Measure the Impact of Shorter, Even Safer EKOS® T

BTG plc (LSE: BTG), the global specialist healthcare company, today highlights the commencement of the KNOCOUT PE study. The KNOCOUT PE study will measure how hospitals and patients are benefitting from a new standard of care in the treatment of Pulmonary Embolism utilizing EKOS® therapy with faster, and even safer protocols, proven effective in the OPTALYSE PE study. Presented in May, the OPTALYSE PE study found pulmonary embolism (PE) can be treated effectively with EKOS® therapy over a much shorter period and at safer thrombolytic doses far below the previous standard.

27 Nov 2017

Appointment of Non-executive Director

BTG plc (LSE: BTG), the global specialist healthcare company, today announces the appointment of Gregory Barrett as a non-executive director of the Board.

BTG Products